Spexis
Switzerland - AllschwilBiotechnology
Focus: Spexis is a Swiss biotechnology company specializing in macrocycle drug development, a modality positioned between small molecules and biologics. With 501-1000 employees and founded in 2005, the company operates as a public entity focused on oncology.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
0
About Spexis
AI assessmentNot HiringNo open roles listed right now. Follow Spexis to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Eribulin
Metastatic Breast CancerClinical Trials (1)
NCT03786094Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Phase 3Help build intelligence for Spexis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.